Start small, dream big: Why a global CRO is the ideal choice for small biotechs

For biotech companies, the journey from protocol to proof is defined by a series of critical decision points. Each one carries weight, shaping timelines, influencing funding, and determining whether a program moves forward or stalls.

The stakes are particularly high for small biotech innovators. Limited runway, lean teams and aggressive development timelines leave little margin for delay. A single enrollment setback, protocol amendment or regulatory challenge can significantly impact funding, timelines and long-term program viability. At the same time, biotech leaders are often balancing scientific strategy, investor expectations and operational execution while pursuing critical development milestones.

Execution matters. But more often than not, the real challenge is not execution alone. It is having the right infrastructure, expertise and insight in place early enough to make confident decisions at every step.

This is why many biotech companies are rethinking how they approach clinical development. Increasingly, they are turning to large, global CROs not just for execution, but for the ability to move forward with greater clarity, speed and confidence.

Access to global infrastructure and patient populations

One of the most immediate advantages of partnering with a large CRO is access to sites, patients and operational infrastructure that would otherwise take years to build.

Established global site networks mean investigators are already trained, qualified and ready to activate. This dramatically reduces startup timelines compared to building relationships from scratch. For biotech companies operating under tight timelines and limited resources, time savings are critical.

Access to broader patient populations is equally important. Enrollment delays remain one of the most common causes of trial disruption. Large CROs can tap into global patient pools, registries and real-world data sources to identify and pre-screen candidates earlier, helping trials start faster and progress more predictably.

Geographic diversification further reduces risk. By distributing enrollment across multiple regions, sponsors are less exposed to disruptions caused by local regulatory delays, geopolitical issues or unexpected site-level challenges.

At the same time, global scale does not come at the expense of local expertise. In-country teams bring a deep understanding of local health care systems, regulatory expectations, language and site relationships, enabling smoother execution on the ground.

Together, these capabilities allow biotech companies to generate data faster, reduce uncertainty and make more informed development decisions, supported by therapeutic expertise applied early in the process.

Regulatory expertise across multiple markets

For biotech companies, navigating regulatory complexity is often one of the most resource-intensive and high-risk aspects of development.

Major CRO partners bring experience across multiple regulatory agencies, enabling the design of trials that satisfy FDA, EMA and other global requirements simultaneously. This reduces the likelihood of costly protocol amendments later in development and supports more efficient, globally aligned submissions.

Established relationships with regulatory authorities also matter. CROs that have supported thousands of interactions understand how agencies interpret data, evaluate risk and respond to different development strategies. This insight allows sponsors to anticipate questions and address gaps early.

Regulatory landscapes are also constantly evolving, from decentralized trial guidance to adaptive designs and population requirements. Dedicated regulatory intelligence teams track these changes in real time, ensuring programs remain aligned with current expectations.

Perhaps most importantly, early identification of regulatory gaps prevents downstream delays that are far more costly to fix. For biotech companies operating under tight timelines and funding constraints, avoiding preventable delays early can directly impact runway and long-term program viability.

Operational scalability and therapeutic expertise

Biotech teams are often balancing scientific strategy, fundraising, investor communication and operational oversight simultaneously, making scalable, experienced support essential to maintaining momentum.

Large CROs provide the ability to scale resources up or down based on the needs of each phase without the burden of maintaining a fixed internal infrastructure. This flexibility allows sponsors to focus their internal teams on strategy while relying on experienced partners for execution. It also provides access to complementary expertise, technologies and supporting services through a single integrated partner, reducing the complexity of managing multiple vendors as program needs evolve.

Applied therapeutic expertise, not just knowledge, is another key differentiator. Therapeutic expertise creates value when it is applied early to inform study design, anticipate risks and guide execution. Rather than reacting to challenges as they emerge, experienced teams identify and address them before they impact timelines or outcomes.

Continuity across the development life cycle also plays a critical role. From early-phase studies through pivotal trials and post-marketing commitments, a single partner can carry knowledge, relationships and context forward, reducing fragmentation and improving efficiency.

Cross-functional integration further reduces complexity. Coordinating across clinical operations, data management, biostatistics, regulatory and medical writing is inherently challenging. Large CROs streamline this coordination, reducing communication overhead and enabling more cohesive execution.

Technology and data capabilities

Technology has become central to modern clinical development, but building and maintaining a robust tech stack can be both complex and cost-prohibitive for biotech companies.

Standing up systems such as EDC, CTMS, analytics platforms and integrated data environments requires significant upfront investment, ongoing maintenance and specialized expertise. For many organizations, this creates a barrier to adoption. It also diverts time, capital and internal resources away from core scientific and development priorities.

Large CROs remove that barrier by providing immediate access to established, validated systems and platforms without the need for independent build-out.

These capabilities extend beyond infrastructure. Advanced analytics and centralized monitoring tools help identify data anomalies and emerging risks earlier, reducing the need for costly interventions while improving study oversight and data quality. Decentralized and hybrid trial models improve patient access, retention and diversity through technologies such as telemedicine, eConsent, eCOA/ePRO, wearables and home health services.

AI is increasingly being applied across multiple stages of clinical development, from study design and feasibility to site selection, enrollment forecasting, monitoring and regulatory preparation. When used effectively, these tools help identify and mitigate risks earlier, improve forecasting, support more informed decision-making, reduce costly downstream disruptions and accelerate development timelines.

Data standardization is another critical advantage. Applying CDISC standards consistently ensures that data is submission-ready, reducing the time and effort required to prepare regulatory filings.

Integrated lab, biomarker, genomics and imaging capabilities further streamline sample management and data integration, improving both efficiency and data quality.

Credibility with investors and partners

Beyond execution, CRO selection plays a meaningful role in how a program is perceived by external stakeholders.

For investors, the involvement of a recognized global CRO signals operational strength and reduces perceived execution risk. It demonstrates that the program is being managed with experienced oversight and established processes.

For potential partners or acquirers, trial quality and execution are key considerations. Well-run trials supported by a reputable CRO strengthen a program’s attractiveness in licensing and co-development discussions. Access to timely, high-quality data also supports critical inflection points such as investor fundraising, partnership discussions and out-licensing opportunities.

CRO partnerships are also often evaluated during due diligence. Choosing a partner with a strong track record of successful submissions reinforces confidence in both the program and the organization behind it.

In addition, global relationships with key opinion leaders and academic centers enhances the scientific credibility of study design and publications, further strengthening the overall narrative.

Taken together, these advantages provide the capabilities, expertise and scale needed to execute world-class clinical programs while maintaining focus on innovation and growth.

Global strength fit for biotech

For small biotech companies, the path from protocol to proof is narrow, and every decision point carries significant risk.

As programs progress, the ability to move forward with confidence becomes just as important as the ability to execute. That confidence comes from having the right partner with the right expertise, infrastructure and alignment in place early — not after challenges emerge.

The PPD™ clinical research business of Thermo Fisher Scientific supports small biotech companies through a biotech-focused operating model that combines deep therapeutic expertise, global infrastructure and integrated capabilities across the development life cycle. Our teams are built to adapt as our biotech clients evolve, providing the flexibility, personal attention and scalable support needed to move programs forward with confidence.

By applying therapeutic expertise early and continuously across programs, we inform study design, anticipate risk and enable more confident decision-making. By aligning clinical strategy, regulatory insight, operational execution and supporting technologies from the outset, we enable sponsors to reduce risk, avoid unnecessary rework and maintain momentum across their programs.

Our teams operate as a true extension of your organization, scaling as needed to achieve the goals of your program while maintaining continuity and coordination throughout the development process.

Some sponsors may assume that working with a large CRO means sacrificing agility or becoming a lower priority. In reality, the right partner combines global scale with a biotech-focused approach, providing dedicated teams, tailored support and the flexibility to adapt as programs evolve.

The result is not just well-executed trials, but the ability to move from one decision point to the next with greater clarity, confidence and control.

Let’s move forward together

For biotech companies, success is not just about advancing a program. It is about advancing it efficiently, strategically and with confidence. Are your programs set up to support confident decision-making at every stage?

When you choose PPD Biotech Solutions, you gain biotech-first services backed by the full strength and capabilities of a leading global CRO.